Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Laserphyrin
2. Mono-l-aspartyl Chlorin E6
3. Monoaspartyl Chlorin E6
4. N-aspartyl Chlorin E6
5. N-aspartylchlorin E6
6. Npe6
7. Talaporfin
1. Laserphyrin
2. 220201-34-3
3. Taporfin Sodium
4. Mono-l-aspartyl Chlorin E6
5. Npe6
6. Ls-11
7. Talaporfin Sodium [usan]
8. Talaporfin Tetrasodium Salt
9. Me-2906
10. L63605pz70
11. Me 2906
12. Tetrasodium (2s)-2-((((7s,8s)-3-carboxylato-7-(2-carboxylatoethyl)-13-ethenyl-18-ethyl-2,8,12,17-tetramethyl-7,8-dihydroporphyrin-5-yl)acetyl)amino)butanedioate
13. Tetrasodium;(2s)-2-[[2-[(2s,3s)-7-carboxylato-3-(2-carboxylatoethyl)-17-ethenyl-12-ethyl-2,8,13,18-tetramethyl-2,3,23,24-tetrahydroporphyrin-5-yl]acetyl]amino]butanedioate
14. Aptocine
15. L-aspartic Acid, N-(((7s,8s)-3-carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-21h,23h-porphin-5-yl)acetyl)-, Tetrasodium Salt
16. Talaporfinsodium
17. Laserphyrin (tn)
18. Ls 11 (photosensitizer)
19. Ls11
20. Talaporfin Sodium (jan/usan)
21. Talaporfin Sodium [jan]
22. Chembl2107806
23. Unii-l63605pz70
24. Dtxsid70420519
25. Talaporfin Sodium [mart.]
26. Talaporfin Sodium [who-dd]
27. Me2906
28. At34139
29. Talaporfin Tetrasodium Salt [mi]
30. D01985
31. Q27282754
32. 220680-62-6
| Molecular Weight | 799.7 g/mol |
|---|---|
| Molecular Formula | C38H37N5Na4O9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 8 |
| Exact Mass | 799.21820490 g/mol |
| Monoisotopic Mass | 799.21820490 g/mol |
| Topological Polar Surface Area | 247 Ų |
| Heavy Atom Count | 56 |
| Formal Charge | 0 |
| Complexity | 1340 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 5 |
Investigated for use/treatment in macular degeneration.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Photosensitizing Agents
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)
Light Sciences Oncology (LSO) aims to en-light-en cancer patients. Light Sciences has developed Light Infusion Therapy (Litx) which is a novel treatment for solid tumors. The therapy involves inserting a flexible light-emitting diode (LED) into a tumor, followed by an injection of LS11 (talaporfin sodium), a light-activated drug. Once the LED activates LS11, molecular oxygen is converted into singlet oxygen, killing tissue within the LED's scope and shutting down the blood supply to the area. The treatment is designed for use on three types of cancers: hepatoma (liver cancer), metastatic colorectal cancer, and Gioma (brain tumor).
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22405
Submission : 2009-01-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18775
Submission : 2005-09-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14914
Submission : 2000-06-06
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
07 May 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
A Talaporfin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Talaporfin, including repackagers and relabelers. The FDA regulates Talaporfin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Talaporfin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Talaporfin supplier is an individual or a company that provides Talaporfin active pharmaceutical ingredient (API) or Talaporfin finished formulations upon request. The Talaporfin suppliers may include Talaporfin API manufacturers, exporters, distributors and traders.
click here to find a list of Talaporfin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Talaporfin DMF (Drug Master File) is a document detailing the whole manufacturing process of Talaporfin active pharmaceutical ingredient (API) in detail. Different forms of Talaporfin DMFs exist exist since differing nations have different regulations, such as Talaporfin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Talaporfin DMF submitted to regulatory agencies in the US is known as a USDMF. Talaporfin USDMF includes data on Talaporfin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Talaporfin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Talaporfin suppliers with USDMF on PharmaCompass.
Talaporfin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Talaporfin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Talaporfin GMP manufacturer or Talaporfin GMP API supplier for your needs.
A Talaporfin CoA (Certificate of Analysis) is a formal document that attests to Talaporfin's compliance with Talaporfin specifications and serves as a tool for batch-level quality control.
Talaporfin CoA mostly includes findings from lab analyses of a specific batch. For each Talaporfin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Talaporfin may be tested according to a variety of international standards, such as European Pharmacopoeia (Talaporfin EP), Talaporfin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Talaporfin USP).
LOOKING FOR A SUPPLIER?
Comment (2)
